Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 11/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104191 | 0.89 | GAA (0.70) | GAAGABRA2GABRB2CYP1A2CYP2C9 | |
| SCHEMBL118187 | 0.82 | GAA (0.75) | GAAGABRA2GABRB2CYP1A2CYP2C9 | |
| SCHEMBL3499867 | 0.81 | GABRA2 (0.57) | GAAGABRA2GABRB2CYP1A2CYP2C9 | |
| SCHEMBL3497394 | 0.81 | PPP1CA (0.48) | GABRA2GABRB2PTGS2 | |
| SCHEMBL101291 | 0.79 | GAA (1.00) | GAAGABRA2GABRB2CYP1A2CYP2C9 | |
| SCHEMBL3499130 | 0.78 | GABRA2 (0.62) | GAAGABRA2GABRB2PTGS2SLC2A2 | |
| SCHEMBL8610256 | 0.78 | GAA (0.71) | GAAGABRA2GABRB2CYP1A2CYP2C9 | |
| SCHEMBL23530875 | 0.77 | GAA (0.75) | GAAGABRA2GABRB2CYP1A2CYP2C9 | |
| SCHEMBL3033258 | 0.77 | GAA (0.75) | GAAGABRA2GABRB2CYP1A2CYP2C9 | |
| SCHEMBL102137 | 0.77 | GAA (0.75) | GAAGABRA2GABRB2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | GAA 4620/4885GABRA2 317/4885GABRB2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.